Table 2 Cox regression analysis of DFS and OS in NAC subgroup (n = 99).
From: BRCAness as a prognostic indicator in patients with early breast cancer
Factor | Disease free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | P Value | HR | 95% CI | P Value | |
Univariate analysis | ||||||
Tumor size (> 2 cm vs. ≤ 2 cm) | 2.912 | 0.697–12.173 | 0.143 | 0.997 | 0.225–4.422 | 0.966 |
Lymph node status (positive vs. negative) | 1.884 | 0.900–3.944 | 0.093 | 0.832 | 0.296–2.341 | 0.728 |
TNM stage (III vs. I–II) | 1.328 | 0.646–2.729 | 0.441 | 0.686 | 0.194–2.434 | 0.560 |
Nuclear grade (III vs. I–II) | 1.484 | 0.705–3.124 | 0.298 | 1.937 | 0.630–5.954 | 0.248 |
Hormone receptor (positive vs. negative) | 0.272 | 0.121–0.610 | 0.002 a | 0.016 | 0.001–1.085 | 0.055 |
Molecular subtype (TNBC vs. non-TNBC) | 2.676 | 1.304–5.492 | 0.007 a | 5.207 | 1.449–18.706 | 0.011 a |
Pathological response (pCR vs. non-pCR) | 0.113 | 0.015–0.827 | 0.032 a | N/A | N/A | N/A |
Clinical response (CR + PR vs. SD + PD) | 0.862 | 0.412–1.805 | 0.694 | 0.523 | 0.185–1.477 | 0.221 |
BRCAness status (positive vs. negative) | 3.966 | 1.978–7.954 | < 0.001 a | 6.145 | 1.943–19.441 | 0.002 a |
Multivariate analysis | ||||||
Molecular subtype (TNBC vs. non-TNBC) | 2.758 | 1.037–7.340 | 0.042 a | 4.126 | 0.817–20.841 | 0.086 |
Pathological response (pCR vs. non-pCR) | 0.054 | 0.007–0.422 | 0.005 a | N/A | N/A | N/A |
Clinical response (CR + PR vs. SD + PD) | 2.034 | 0.910–4.547 | 0.083 | 1.215 | 0.411–3.597 | 0.724 |
BRCAness status (positive vs. negative) | 2.962 | 1.184–7.412 | 0.020 a | 2.681 | 0.618–11.630 | 0.188 |
